BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25030290)

  • 1. FDG PET/CT: normal variations and benign findings--translation to PET/MRI.
    Beheshti M; Kim CK
    PET Clin; 2014 Apr; 9(2):xiii-xiv. PubMed ID: 25030290
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
    Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
    Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
    Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
    Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI.
    Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of pulmonary tumor thrombosis by integrated 18F-FDG PET/CT scans with intravenous contrast].
    Valls E; Garcia JR; Rodriguez R; Soler M; Moragas M; Lomeña F
    Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):49-51. PubMed ID: 23177345
    [No Abstract]   [Full Text] [Related]  

  • 11. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
    Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?
    Bitencourt AG; Lima EN; Chojniak R; Marques EF; Souza JA; Andrade WP; Guimarães MD
    Eur J Radiol; 2014 Aug; 83(8):1381-6. PubMed ID: 24931922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET/CT in the management of colorectal and anal cancers.
    Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Syndromic abdominal ganglioneuroma: a rare cause of false-positive findings in the F-18 FDG PET / CT in neurofibromatosis type 1].
    Derlin T; Hagel C; Mautner VF
    Rofo; 2014 Jul; 186(7):706-7. PubMed ID: 24407706
    [No Abstract]   [Full Text] [Related]  

  • 18. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.